Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Teva Reports Second Quarter 2018 Financial Results
August 2, 2018 7:00 AM EDTRevenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 Non-GAAP diluted EPS of $0.78 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and in total $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.55-2.80 from $2.40-$2.65 Free cash flow guidance raised to $3.2-3.4 billion from $3.0-3.2 billion
JERUSALEM--(BUSINESS WIRE)--... More
